Literature DB >> 30294754

Recent advances in experimental polyphosphazene adjuvants and their mechanisms of action.

Royford Magiri1,2, George Mutwiri1,2, Heather L Wilson3,4,5.   

Abstract

Vaccination continues to be a very important public health intervention to control infectious diseases in the world. Subunit vaccines are generally poorly immunogenic and require the addition of adjuvants to induce protective immune responses. Despite their critical role in vaccines, adjuvant mechanism of action remains poorly understood, which is a barrier to the development of new, safe and effective vaccines. In the present review, we focus on recent progress in understanding the mechanisms of action of the experimental adjuvants poly[di(carboxylatophenoxy)phosphazene] (PCPP) and poly[di(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) (in this review, adjuvants PCPP and PCEP are collectively referred to as PZ denoting polyphosphazenes). PZs are high molecular weight, water-soluble, synthetic polymers that have been shown to regulate innate immune response genes, induce cytokines and chemokines secretion at the site of injection and, also, induce immune cell recruitment to the site of injection to create a local immune-competent environment. There is an evidence that as well as its role as an immunoadjuvant (that activate innate immune responses), PZ can also act as a vaccine carrier. The mechanism of action that explains how PZ leads to these effects is not known and is a barrier to the development of designer vaccines.

Entities:  

Keywords:  Adjuvant; Innate immunity; Mechanism of action; Polyphosphazene; Vaccine

Mesh:

Substances:

Year:  2018        PMID: 30294754     DOI: 10.1007/s00441-018-2929-4

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  7 in total

Review 1.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

2.  Protein-loaded soluble and nanoparticulate formulations of ionic polyphosphazenes and their interactions on molecular and cellular levels.

Authors:  Alexander K Andrianov; Alexander Marin; Joseph Deng; Thomas R Fuerst
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2019-09-09       Impact factor: 7.328

3.  Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.

Authors:  Sarah M Valencia; Athina Zacharia; Alexander Marin; Rebecca L Matthews; Chia-Kuei Wu; Breana Myers; Chelsea Sanders; Simone Difilippantonio; Reinhard Kirnbauer; Richard B Roden; Ligia A Pinto; Robert H Shoemaker; Alexander K Andrianov; Jason D Marshall
Journal:  Hum Vaccin Immunother       Date:  2021-02-11       Impact factor: 3.452

Review 4.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

Review 5.  Main-Chain Phosphorus-Containing Polymers for Therapeutic Applications.

Authors:  Paul Strasser; Ian Teasdale
Journal:  Molecules       Date:  2020-04-08       Impact factor: 4.411

6.  Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine.

Authors:  Alexander Marin; Ananda Chowdhury; Sarah M Valencia; Athina Zacharia; Reinhard Kirnbauer; Richard B S Roden; Ligia A Pinto; Robert H Shoemaker; Jason D Marshall; Alexander K Andrianov
Journal:  Nanomedicine       Date:  2021-01-18       Impact factor: 5.307

7.  In Vivo and In Vitro Potency of Polyphosphazene Immunoadjuvants with Hepatitis C Virus Antigen and the Role of Their Supramolecular Assembly.

Authors:  Alexander K Andrianov; Alexander Marin; Ruixue Wang; Ananda Chowdhury; Pragati Agnihotri; Abdul S Yunus; Brian G Pierce; Roy A Mariuzza; Thomas R Fuerst
Journal:  Mol Pharm       Date:  2020-06-23       Impact factor: 4.939

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.